PYXS
Pyxis Oncology, Inc. NASDAQ Listed Oct 8, 2021$2.13
+4.93%
vs $2.03
Mkt Cap $133.8M
52w Low $1.04
25.3% of range
52w High $5.34
50d MA $1.89
200d MA $2.30
P/E (TTM)
-1.6x
EV/EBITDA
—
P/B
2.5x
Debt/Equity
0.3x
ROE
-149.1%
P/FCF
-2.1x
RSI (14)
71.30
ATR (14)
$0.16
Beta
1.42
50d MA
$1.89
200d MA
$2.30
Avg Volume
588.9K
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
321 HARRISON AVENUE · BOSTON, MA 02118 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -0.35 | -0.37 | -5.7% | 2.62 | +1.1% | -15.6% | +3.2% | -11.4% | -5.4% | +4.7% | — |
| Mar 23, 2026 | BMO | -0.35 | -0.29 | +17.1% | 1.42 | +1.4% | -4.2% | +5.1% | -2.8% | -5.8% | -3.1% | — |
| Nov 3, 2025 | BMO | -0.36 | -0.35 | +2.8% | 3.81 | +0.8% | +2.4% | +0.3% | +3.3% | -3.2% | +22.0% | — |
| Aug 14, 2025 | BMO | -0.36 | -0.30 | +16.7% | 1.13 | +1.8% | +8.8% | +0.8% | -3.2% | -3.3% | +13.8% | — |
| May 15, 2025 | BMO | -0.29 | -0.35 | -20.7% | 1.11 | +0.0% | +9.0% | +1.7% | -1.6% | -5.0% | +4.3% | — |
| Mar 18, 2025 | BMO | -0.33 | -0.32 | +3.0% | 1.06 | +1.9% | +0.9% | +4.7% | +8.0% | -0.8% | -4.2% | — |
| Nov 12, 2024 | BMO | -0.32 | -0.35 | -9.4% | 4.62 | +2.8% | -7.4% | +0.0% | -2.1% | -2.4% | +1.7% | — |
| Aug 14, 2024 | BMO | -0.33 | -0.29 | +12.1% | 3.36 | -0.9% | +2.1% | -2.0% | +7.7% | -1.9% | +2.3% | — |
| May 14, 2024 | BMO | -0.27 | -0.06 | +77.8% | 4.20 | +1.0% | +0.2% | -1.0% | -0.5% | +1.0% | -4.5% | — |
| Mar 21, 2024 | BMO | -0.49 | -0.33 | +32.7% | 4.96 | -0.6% | -19.6% | -8.5% | +4.9% | +9.7% | +1.4% | — |
| Nov 7, 2023 | BMO | -0.57 | -0.56 | +1.8% | 1.66 | +0.0% | -1.8% | -8.0% | +2.0% | +2.0% | -0.6% | — |
| Aug 11, 2023 | BMO | -0.66 | -0.41 | +37.9% | 2.58 | -1.9% | -5.0% | -0.4% | -2.5% | -5.5% | -3.6% | — |
| May 11, 2023 | AMC | -0.84 | -0.54 | +35.7% | 3.04 | +1.6% | +7.9% | +13.7% | -4.8% | +4.5% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Wedbush | Initiates | Outperform | $6 | $1.76 | $1.88 | +6.8% | +4.0% | +25.7% | -1.7% | +21.2% | +0.4% |
| Mar 24 | Stifel | Maintains | Buy → Buy | — | $1.42 | $1.44 | +1.4% | -4.2% | +5.1% | -2.8% | -5.8% | -3.1% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.44 | +1.4% | -4.2% | +5.1% | -2.8% | -5.8% | -3.1% |
| Dec 19 | RBC Capital | Maintains | Outperform → Outperform | — | $1.73 | $1.75 | +1.2% | -26.6% | -6.3% | -8.4% | +1.8% | +0.0% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.75 | +1.2% | -26.6% | -6.3% | -8.4% | +1.8% | +0.0% |
| Nov 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.80 | $5.05 | +5.2% | +7.3% | +3.7% | -1.1% | -1.7% | -15.4% |
| Nov 4 | Guggenheim | Maintains | Buy → Buy | — | $3.81 | $3.84 | +0.8% | +2.4% | +0.3% | +3.3% | -3.2% | +22.0% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.24 | $1.23 | -0.8% | -3.2% | -3.3% | +13.8% | +1.5% | +3.7% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.17 | -3.3% | +1.7% | -1.6% | -5.0% | +4.3% | +2.5% |
| Mar 19 | RBC Capital | Maintains | Outperform → Outperform | — | $1.06 | $1.08 | +1.9% | +0.9% | +4.7% | +8.0% | -0.8% | -4.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.08 | +1.9% | +0.9% | +4.7% | +8.0% | -0.8% | -4.2% |
| Dec 20 | RBC Capital | Maintains | Outperform → Outperform | — | $1.54 | $1.54 | +0.0% | +9.7% | -1.2% | -4.2% | +1.2% | -1.9% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.54 | +0.0% | +9.7% | -1.2% | -4.2% | +1.2% | -1.9% |
| Nov 21 | William Blair | Downgrade | Outperform → Market Perform | — | $3.82 | $2.17 | -43.2% | -45.0% | -9.5% | -0.5% | -6.3% | +3.4% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $3.82 | $2.17 | -43.2% | -45.0% | -9.5% | -0.5% | -6.3% | +3.4% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.82 | $2.17 | -43.2% | -45.0% | -9.5% | -0.5% | -6.3% | +3.4% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $3.66 | $3.75 | +2.5% | +0.5% | +0.3% | -2.4% | +0.0% | -2.5% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.43 | $3.44 | +0.3% | -2.0% | +7.7% | -1.9% | +2.3% | +0.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.21 | $4.21 | +0.0% | -1.0% | -0.5% | +1.0% | -4.5% | -2.5% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.35 | $5.25 | -1.9% | -5.0% | +3.7% | -6.6% | -3.7% | -1.1% |
| Mar 22 | RBC Capital | Maintains | Outperform → Outperform | — | $4.96 | $4.93 | -0.6% | -19.6% | -8.5% | +4.9% | +9.7% | +1.4% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.96 | $4.93 | -0.6% | -19.6% | -8.5% | +4.9% | +9.7% | +1.4% |
| Mar 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $2.20 | $2.13 | -3.2% | -12.3% | +14.5% | +22.2% | +42.6% | +17.9% |
| Nov 2 | Jefferies | Maintains | Buy → Buy | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.0% | +0.5% | -11.4% | -14.0% |
| Nov 2 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.0% | +0.5% | -11.4% | -14.0% |
| Nov 2 | BofA Securities | Maintains | Neutral → Neutral | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.0% | +0.5% | -11.4% | -14.0% |
No insider trades available.
8-K · 2.02
!! High
Pyxis Oncology, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Pyxus Pharmaceuticals provided a year-end business update and financial results, but the vague 8-K disclosure suggests management may be withholding material information from full public disclosure, warranting investor caution.
Mar 23
8-K · 5.02
!!! Very High
Pyxis Oncology, Inc. -- 8-K 5.02: Executive Change
Pyxis Oncology appoints Tom Civik as President effective February 2, 2026, signaling potential strategic shifts in leadership and operational direction for the oncology-focused company.
Feb 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Pfizer Inc | 7,032,770 | $9M | — | Mar 2026 |
| 2 | Gordonmd Global Investments Lp | 4,121,870 | $6M | — | Mar 2026 |
| 3 | Laurion Capital Management Lp | 4,796,479 | $6M | Added | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 2,033,510 | $3M | New | Mar 2026 |
| 5 | Renaissance Technologies Llc | 888,680 | $1M | Added | Mar 2026 |
| 6 | Jane Street Group, Llc | 786,010 | $904K | Added | Dec 2025 |
| 7 | Longaeva Partners L.p. | 503,214 | $735K | — | Mar 2026 |
| 8 | Millennium Management | 397,625 | $581K | Reduced | Mar 2026 |
| 9 | Marshall Wace, Llp | 354,417 | $517K | Reduced | Mar 2026 |
| 10 | Decheng Capital Llc | 326,810 | $477K | — | Mar 2026 |
| 11 | Ubs Group Ag | 254,124 | $371K | Reduced | Mar 2026 |
| 12 | Acadian Asset Management Llc | 144,256 | $209K | New | Mar 2026 |
| 13 | Morgan Stanley | 178,444 | $205K | Reduced | Dec 2025 |
| 14 | Bank Of New York Mellon Corp | 133,996 | $196K | Reduced | Mar 2026 |
| 15 | Northern Trust Corp | 101,948 | $149K | — | Mar 2026 |
| 16 | J. Derek Lewis & Associates Inc. | 96,000 | $124K | Reduced | Mar 2026 |
| 17 | Two Sigma Investments, Lp | 73,300 | $107K | Reduced | Mar 2026 |
| 18 | Panagora Asset Management Inc | 69,424 | $101K | New | Mar 2026 |
| 19 | Citadel Advisors Llc | 61,249 | $89K | Reduced | Mar 2026 |
| 20 | Toronto Dominion Bank | 75,000 | $86K | New | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 345,130 | $504K | Mar 2026 |
| 2 | Fidelity Extended Market Index Fund | 275,610 | $405K | Feb 2026 |
| 3 | iShares Micro-Cap ETF | 123,828 | $181K | Mar 2026 |
| 4 | Fidelity Total Market Index Fund | 90,276 | $133K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 75,417 | $111K | Feb 2026 |
| 6 | Ultra-Small Company Market Fund | 70,060 | $102K | Mar 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 30,129 | $44K | Feb 2026 |
| 8 | Dimensional U.S. Small Cap ETF | 18,887 | $27K | Jan 2026 |
| 9 | Victory Extended Market Index Fund | 4,794 | $7K | Jan 2026 |
| 10 | Invesco Nasdaq Biotechnology ETF | 3,526 | $5K | Feb 2026 |
| 11 | ProShares Ultra Nasdaq Biotechnology | 2,875 | $4K | Feb 2026 |
| 12 | Guggenheim Active Allocation Fund | 62 | $91 | Feb 2026 |
Valuation
Market Cap
$133.8M
Enterprise Value
$135.4M
P/E (TTM)
-1.63x
Forward P/E
—
PEG Ratio
0.30x
P/B
2.51x
P/S
9.66x
P/FCF
-2.11x
EV/EBITDA
—
Shares Out
62.8M
Financials (TTM)
Revenue
$13.9M
Net Income
-$81.7M
EBITDA
-$75.9M
Free Cash Flow
-$63.5M
Op Cash Flow
-$63.5M
EPS Basic
$-1.28
EPS Diluted
$-1.31
EPS Forward
$-1.30
Gross Margin
99.8%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$91.5M
Total Liab.
$38.1M
Total Equity
$53.4M
Cash
$15.4M
LT Debt
$17.0M
Book Value/Sh
$0.85
Debt/Equity
0.35x
Current Ratio
3.41
Quick Ratio
3.41
Returns & Growth
ROE
-149.1%
ROA
-87.0%
ROIC
-117.1%
Rev Growth YoY
-14.2%
EPS Growth YoY
+3.0%
Price Returns
2W
-18.6%
1M
+5.9%
3M
+22.4%
6M
-65.3%
12M
+48.8%
Technicals
52W High
$5.34
52W Low
$1.04
50d MA
$1.89
200d MA
$2.30
RSI (14)
71.30
ATR (14)
$0.16
Beta
1.42
Avg Volume
589K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.67
High
$8.00
Low
$5.00
Median
$7.00
Data updated apr 26, 2026 9:23pm
· Source: financialmodelingprep.com